Business UpdateAug 10, 2026, 04:11 PM
Fractyl Health Warns of Going Concern Doubt; Nasdaq Non-Compliance
AI Summary
Fractyl Health, Inc. disclosed substantial doubt about its ability to continue as a going concern, with existing cash and cash equivalents of $47.1 million as of June 30, 2026, projected to fund operations only into early 2027. The company also received a Nasdaq notice for non-compliance with the minimum bid price rule. Operationally, Fractyl Health reported a net loss of $(25.5) million for Q2 2026 and is advancing its clinical pipeline, with topline data for the Revita REMAIN-1 Pivotal Cohort expected in early Q4 2026 and the first patient dosing for Rejuva RJVA-001 anticipated in H2 2026.
Key Highlights
- Substantial doubt about Fractyl Health's ability to continue as a going concern.
- Received Nasdaq minimum bid price non-compliance notice on March 13, 2026.
- Cash and cash equivalents totaled $47.1 million as of June 30, 2026.
- Existing cash is projected to fund operations only into early 2027.
- Reported a net loss of $(25.5) million for the three months ended June 30, 2026.
- Accumulated deficit reached $572.6 million as of June 30, 2026.
- Revita REMAIN-1 Pivotal Cohort topline 6-month data anticipated in early Q4 2026.
- Rejuva RJVA-001 first-in-human study expected in H2 2026 after Netherlands CTA authorization.
Price Impact
More from GUTS